Modelling costs of community-based HIV self-testing programmes in Southern Africa at scale: an econometric cost function analysis across five countries.
HIV
health economics
health services research
Journal
BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
01
03
2021
accepted:
25
05
2021
entrez:
19
7
2021
pubmed:
20
7
2021
medline:
7
8
2021
Statut:
ppublish
Résumé
Following success demonstrated with the HIV Self-Testing AfRica Initiative, HIV self-testing (HIVST) is being added to national HIV testing strategies in Southern Africa. An analysis of the costs of scaling up HIVST is needed to inform national plans, but there is a dearth of evidence on methods for forecasting costs at scale from pilot projects. Econometric cost functions (ECFs) apply statistical inference to predict costs; however, we often do not have the luxury of collecting large amounts of location-specific data. We fit an ECF to identify key drivers of costs, then use a simpler model to guide cost projections at scale. We estimated the full economic costs of community-based HIVST distribution in 92 locales across Malawi, Zambia, Zimbabwe, South Africa and Lesotho between June 2016 and June 2019. We fitted a cost function with determinants related to scale, locales organisational and environmental characteristics, target populations, and per capita Growth Domestic Product (GDP). We used models differing in data intensity to predict costs at scale. We compared predicted estimates with scale-up costs in Lesotho observed over a 2-year period. The scale of distribution, type of community-based intervention, percentage of kits distributed to men, distance from implementer's warehouse and per capita GDP predicted average costs per HIVST kit distributed. Our model simplification approach showed that a parsimonious model could predict costs without losing accuracy. Overall, ECF showed a good predictive capacity, that is, forecast costs were close to observed costs. However, at larger scale, variations of programme efficiency over time (number of kits distributed per agent monthly) could potentially influence cost predictions. Our empirical cost function can inform community-based HIVST scale-up in Southern African countries. Our findings suggest that a parsimonious ECF can be used to forecast costs at scale in the context of financial planning and budgeting.
Sections du résumé
BACKGROUND
Following success demonstrated with the HIV Self-Testing AfRica Initiative, HIV self-testing (HIVST) is being added to national HIV testing strategies in Southern Africa. An analysis of the costs of scaling up HIVST is needed to inform national plans, but there is a dearth of evidence on methods for forecasting costs at scale from pilot projects. Econometric cost functions (ECFs) apply statistical inference to predict costs; however, we often do not have the luxury of collecting large amounts of location-specific data. We fit an ECF to identify key drivers of costs, then use a simpler model to guide cost projections at scale.
METHODS
We estimated the full economic costs of community-based HIVST distribution in 92 locales across Malawi, Zambia, Zimbabwe, South Africa and Lesotho between June 2016 and June 2019. We fitted a cost function with determinants related to scale, locales organisational and environmental characteristics, target populations, and per capita Growth Domestic Product (GDP). We used models differing in data intensity to predict costs at scale. We compared predicted estimates with scale-up costs in Lesotho observed over a 2-year period.
RESULTS
The scale of distribution, type of community-based intervention, percentage of kits distributed to men, distance from implementer's warehouse and per capita GDP predicted average costs per HIVST kit distributed. Our model simplification approach showed that a parsimonious model could predict costs without losing accuracy. Overall, ECF showed a good predictive capacity, that is, forecast costs were close to observed costs. However, at larger scale, variations of programme efficiency over time (number of kits distributed per agent monthly) could potentially influence cost predictions.
DISCUSSION
Our empirical cost function can inform community-based HIVST scale-up in Southern African countries. Our findings suggest that a parsimonious ECF can be used to forecast costs at scale in the context of financial planning and budgeting.
Identifiants
pubmed: 34275875
pii: bmjgh-2021-005554
doi: 10.1136/bmjgh-2021-005554
pmc: PMC8287624
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Informations de copyright
©World Health Organization 2021. Licensee BMJ.
Déclaration de conflit d'intérêts
Competing interests: GBG is currently employed by Sanofi Pasteur, France.
Références
Bull World Health Organ. 2014 Jul 1;92(7):499-511AD
pubmed: 25110375
Sex Transm Infect. 2016 Mar;92(2):130-4
pubmed: 26438349
J Health Econ. 1987 Dec;6(4):305-18
pubmed: 10285440
Sci Rep. 2019 Sep 2;9(1):12621
pubmed: 31477764
Nature. 2015 Dec 3;528(7580):S77-85
pubmed: 26633769
Health Econ. 2023 Oct;32(10):2216-2233
pubmed: 37332114
AIDS. 2018 Sep 10;32(14):2043-2049
pubmed: 29894386
Annu Rev Public Health. 1984;5:193-213
pubmed: 6426487
PLoS One. 2018 Sep 7;13(9):e0201706
pubmed: 30192765
Health Policy Plan. 2017 Dec 1;32(10):1407-1416
pubmed: 29029086
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25245
pubmed: 30907515
AIDS. 2008 Jul;22 Suppl 1:S43-9
pubmed: 18664952
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25244
pubmed: 30907505
Sex Transm Infect. 2010 Feb;86 Suppl 1:i89-94
pubmed: 20167740
Health Econ. 2011 Aug;20(8):897-916
pubmed: 20799344
Lancet HIV. 2019 Feb;6(2):e81-e92
pubmed: 30584047
AIDS. 2017 Jul 1;31 Suppl 3:S203-S212
pubmed: 28665878
PLoS Med. 2012;9(7):e1001247
pubmed: 22802731
Cost Eff Resour Alloc. 2007 Nov 05;5:13
pubmed: 17983475
Health Syst Reform. 2018;4(3):227-238
pubmed: 30207902
AIDS. 2020 Nov 15;34(14):2115-2123
pubmed: 32796213
BMC Health Serv Res. 2009 May 21;9:82
pubmed: 19457269
Afr J AIDS Res. 2019 Dec;18(4):297-305
pubmed: 31779577
BMJ Glob Health. 2021 Jul;6(Suppl 4):
pubmed: 34275876
PLoS One. 2017 Oct 16;12(10):e0185740
pubmed: 29036171
Health Econ. 2016 Feb;25 Suppl 1:53-66
pubmed: 26763594
PLoS Med. 2015 Sep 08;12(9):e1001873
pubmed: 26348035
BMJ Glob Health. 2021 Jul;6(Suppl 4):
pubmed: 34275874
BMC Public Health. 2005 Sep 24;5:98
pubmed: 16181491
Bull World Health Organ. 2005 Oct;83(10):747-55
pubmed: 16283051
Lancet. 2018 May 5;391(10132):1783-1798
pubmed: 29678341
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25255
pubmed: 30907499
J Int AIDS Soc. 2017 May 15;20(1):21594
pubmed: 28530049
Health Econ. 2016 Feb;25 Suppl 1:67-82
pubmed: 26763652
PLoS One. 2012;7(12):e51993
pubmed: 23284843
Health Econ. 2017 Dec;26(12):1644-1666
pubmed: 27976430
BMC Health Serv Res. 2005 Nov 05;5:69
pubmed: 16271151
PLoS One. 2012;7(11):e48726
pubmed: 23144946